Allakos Inc. (ALLK)
Market Cap | 92.92M |
Revenue (ttm) | n/a |
Net Income (ttm) | -178.75M |
Shares Out | 89.34M |
EPS (ttm) | -2.02 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 229,525 |
Open | 1.090 |
Previous Close | 1.080 |
Day's Range | 1.010 - 1.090 |
52-Week Range | 0.540 - 3.410 |
Beta | 0.91 |
Analysts | Hold |
Price Target | 1.67 (+60.58%) |
Earnings Date | Nov 6, 2024 |
About ALLK
Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company’s lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for ALLK stock is "Hold." The 12-month stock price forecast is $1.67, which is an increase of 60.58% from the latest price.
News
Allakos Runs Up Into A Near-Term Catalyst
Allakos shifted focus to AK006 in 2024 after lirentelimab's failure in phase 2 trials for atopic dermatitis and chronic spontaneous urticaria. Phase 1 work with intravenous and subcutaneous AK006 demo...
Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results
SAN CARLOS, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and prolife...
Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers
– Subcutaneously administered AK006 showed approximately 77% bioavailability and prolonged receptor occupancy on mast cells –– Subcutaneous AK006 was well-tolerated with a favorable safety profile –– ...
Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results
SAN CARLOS, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and prolife...
The Schall Law Firm Begins Probe Into Claims Against Allakos Inc And Urges Affected Investors To Participate
LOS ANGELES, CA / ACCESSWIRE / June 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("Al...
The Schall Law Firm Initiates Investigation Into Allegations Against Allakos Inc And Encourages Impacted Investors To Engage
LOS ANGELES, CA / ACCESSWIRE / June 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("Al...
Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile
– AK006 achieved serum concentrations consistent with levels demonstrating inhibitory activity in preclinical experiments –– Skin biopsies from subjects treated with AK006 show high receptor occupancy...
The Schall Law Firm Initiates Investigation Into Allegations Against Allakos Inc And Encourages Impacted Investors To Join
LOS ANGELES, CA / ACCESSWIRE / June 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("Al...
The Schall Law Firm Starts Probe Into Claims Against Allakos Inc And Urges Affected Investors To Participate
LOS ANGELES, CA / ACCESSWIRE / June 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("Al...
The Schall Law Firm Initiates Investigation Into Allegations Against Allakos Inc And Encourages Impacted Investors To Get Involved
LOS ANGELES, CA / ACCESSWIRE / June 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("Al...
Claims Against Allakos Inc The Schall Law Firm Begins Probe And Urges Affected Investors To Participate
LOS ANGELES, CA / ACCESSWIRE / June 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("Al...
Allegations Against Allakos Inc The Schall Law Firm Initiates Investigation And Encourages Impacted Investors To Get Involved
LOS ANGELES, CA / ACCESSWIRE / June 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("Al...
Claims Against Allakos Inc Schall Law Firm Begins Probe And Urges Affected Investors To Participate
LOS ANGELES, CA / ACCESSWIRE / June 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("Al...
Allegations Against Allakos Inc.: Schall Law Firm Initiates Investigation And Encourages Impacted Investors To Get Involved
LOS ANGELES, CA / ACCESSWIRE / June 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("Al...
Charges Against Allakos Inc.: Schall Law Firm Launches Examination And Invites Affected Investors To Participate
LOS ANGELES, CA / ACCESSWIRE / June 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("All...
Accusations Against Allakos Inc.: Schall Law Firm Begins Inquiry And Calls On Impacted Investors To Engage
LOS ANGELES, CA / ACCESSWIRE / June 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("All...
Claims Against Allakos Inc.: Schall Law Firm Initiates Probe And Invites Affected Investors To Connect
LOS ANGELES, CA / ACCESSWIRE / June 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("All...
Allegations Against Allakos Inc.: Schall Law Firm Begins Investigation And Encourages Impacted Investors To Reach Out
LOS ANGELES, CA / ACCESSWIRE / June 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("All...
Allakos Inc. Allegations: Schall Law Firm Initiates Probe and Invites Affected Investors to Connect
LOS ANGELES, CA / ACCESSWIRE / June 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("All...
The Schall Law Firm is Initiating a Probe into Allegations Against Allakos Inc. and Invites Investors who have Suffered losses to Get in Touch
LOS ANGELES, CA / ACCESSWIRE / June 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("All...
ALLK IMPORTANT ACTION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("All...
IMPORTANT ACTION UPDATE: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("All...
IMPORTANT ACTION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("All...
Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria
– Top-line Phase 1 CSU results expected at year end 2024 – SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK006 for the treatment ...
IMPORTANT SHAREHOLDER INVESTIGATION: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("All...